Form D · Biotechnology

OPGEN INC

Rockville, MD · CIK 0001293818

Offering snapshot reported Oct 12, 2022 · SEC filing

Reported sold
$3.38M
Offering amount: $3.38M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 3, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 12, 2022Initial$3,381,338No comparison1SEC filing
Feb 24, 2021Initial$25,000,000No comparison1SEC filing
Dec 4, 2020Initial$9,974,027No comparison1SEC filing
Aug 3, 2018Initial$285,512No comparison1SEC filing
Sep 21, 2017Initial$110,000No comparison1SEC filing
Jun 20, 2017Initial$500,000No comparison2SEC filing
May 27, 2016Initial$7,227,504No comparison10SEC filing
Jul 23, 2015Initial$2,584,090No comparison4SEC filing
Feb 23, 2015Initial$1,243,999No comparison9SEC filing
Jul 17, 2014Initial$1,079,917No comparison4SEC filing
Apr 4, 2014Amendment$3,999,864$1,999,997vs Dec 30, 201329SEC filing
Dec 30, 2013Initial$1,999,867No comparison29SEC filing
Mar 14, 2012Initial$6,100,000No comparison28SEC filing
Feb 16, 2012Amendment$3,532,442$1,400,000vs Dec 9, 201127SEC filing
Dec 9, 2011Initial$2,132,442No comparison27SEC filing
Feb 22, 2011Amendment$11,935,601$2,724,460vs Oct 6, 201033SEC filing
Oct 6, 2010Initial$9,211,141No comparison15SEC filing
May 10, 2010Amendment$4,018,522$18,522vs Mar 31, 201013SEC filing
Mar 31, 2010Initial$4,000,000No comparison11SEC filing
Jan 15, 2010Amendment$4,018,336$2,018,336vs Dec 11, 200914SEC filing
Dec 11, 2009Initial$2,000,000No comparison12SEC filing
Sep 11, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$203K
Finders' fees
$0
Form D file number
021-461438
Represents aggregate gross proceeds from an investor in connection with Issuer's registered direct offering of common stock, preferred stock and pre-funded warrants and a concurrent private placement of common stock purchase warrants.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
H.C. Wainwright & Co., LLC375

Source: Form D, filed Oct 12, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Brian G Atwood Director
Johannes Bacher Executive
Mario Crovetto Director
Harry D'andrea Director
Timothy C. Dec Executive
Colin W. Dykes Executive
R. Donald Elsey Director
Prabhavathi Fernandes Director
Timothy J.R. Harris Director
David Hoekzema Executive
Timothy Howe Director
Evan Jones Director
Kevin Krenitsky Executive
Ronald W. Lennox Director
Laurence R Mc Carthy Director
Corey Mulloy Director
Tina S Nova Director
William E. Rhodes Iii Director
Tom Ross Executive
David M Rubin Director
Bijan Salehizadeh Director
Vadim Sapiro Executive
Oliver Schacht Director, Executive
Misti Ushio Director
Terry Walker Executive
Albert Weber Executive
C. Douglas White Director, Executive
C Eric Winzer Executive
C. Eric Winzer Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9717 Key West Avenue Suite 100
Rockville, MD, 20850